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Introduction: Significant differences in outcome are observed 
among lung cancer patients belonging to the same tumor node metas-
tasis stage, suggesting phenotypic heterogeneity beyond this staging 
algorithm. We used a cluster analysis approach to classify patients 
into distinct phenotypes, and we attempted to validate the clinical 
relevance of these phenotypes by comparing outcome.
Methods: We formed a cohort of all stage I to III non–small-
cell lung cancer patients seen between January 2004 and October 
2010 in a cancer center and followed until death or last follow-
up appointment, with prospectively collected data on clinical and 
tumor characteristics. Multiple correspondence analysis was fol-
lowed by hierarchical clustering to form homogenous clusters of 
patients. Overall survival and disease-free survival estimates were 
compared among clusters.
Results: The cohort included 367 patients (mean follow-up of 2.5 
years), 173 of whom died during that period (191 deaths per 1000 
person-years). A four-cluster model was identified, revealing distinct 
phenotypes with respect to baseline characteristics. Hazard ratios for 
mortality were 8.1, 5.0, and 3.7 (all statistically significant) for clus-
ters 2, 1, and 3, respectively, when compared with cluster 4—with the 
most favorable outcome.
Conclusion: Staging of patients with non–small-cell lung cancer for 
prognostic purposes may be improved by considering phenotypes 
that exhibit significant differences in clinical course and outcome.
Key Words: Non–small-cell lung cancer, Cluster analysis, Phenotypic 
heterogeneity.
(J Thorac Oncol. 2015;10: 754–761)
Lung cancer is the leading cause of cancer-related deaths in Canada, in both men and women, accounting for over 
one-quarter of all cancer deaths.1 Non–small cell lung can-
cer (NSCLC) is the diagnostic entity in the vast majority of 
cases. Up to now, the only firmly established prognostic tools 
are the tumor node metastasis (TNM) staging system and per-
formance status (PS).2,3 However, the potential of those two 
prognostic factors to accurately predict overall survival (OS) 
and disease-free survival (DFS) is limited. In fact, there are 
significant interindividual differences with respect to dis-
ease course and outcome, even within the same TNM stage. 
Such findings are indicative of the phenotypic heterogene-
ity of NSCLC, beyond the TNM staging system. Identifying 
patients with a higher likelihood of poor outcome would allow 
optimization of patient care by offering individually tailored 
treatment strategies.
Defining clinical phenotypes of NSCLC with specific 
patterns of disease presentation, based on a simultaneous anal-
ysis of various demographic, clinical, pathologic, molecular, 
and genetic features, would be an interesting and novel meth-
odology that has never been performed in lung cancer patient 
cohorts, to the best of our knowledge. Such an approach may 
be done, using statistical techniques, such as cluster analysis. 
The latter is a multivariate statistical technique that has been 
successfully used to classify asthma patients into phenotypes 
with distinctive clinical, physiologic, and pathologic parame-
ters.4–7 We hypothesized that NSCLC has distinct phenotypes, 
each being associated with a different clinical presentation, 
course, and outcome.
MATERIALS AND METHODS
A review of prospectively collected data from con-
secutive patients with stages I to III NSCLC, diagnosed 
between January 2004 and December 2010 and followed at a 
single tertiary care referral center (Jewish General Hospital, 
Montreal, Canada), was undertaken. The population analyzed 
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in this study consisted of patients with a diagnosis of poten-
tially curable, clinically or pathologically proven stages I to 
III NSCLC. Patients were excluded if they entered the cohort 
with a second primary, recurrent disease, or distant metastatic 
involvement (stage IV NSCLC).
We attempted to collect missing data, by reviewing elec-
tronic and/or paper medical records, and contacting staff at the 
Pathology Laboratory and Nuclear Medicine Division.
Cluster and Multiple Correspondence 
Analysis Methodology
We employed two complementary statistical tech-
niques to define specific phenotypes within our patient 
cohort: multiple correspondence analysis (MCA) and clus-
ter analysis. MCA is a principal component analysis method 
that assigns numerical scores to subjects and categories of 
categorical variables and captures the relative associations 
among them,8 by generating a graphical display of catego-
ries as data points in a high-dimensional “Euclidian” space. 
This technique, therefore, allows a reduction in the number 
of variables needed to summarize the data. The MCA output 
provides several dimensional solutions; the optimal solution 
is selected on the basis of the smallest number of dimensions 
that would account for the largest total explained variance. 
A set of continuous coordinates is generated, and a continuous 
similarity measure—the Euclidian distance—is used to deter-
mine similarity between observations. A linkage method is 
then applied to determine distance between clusters or groups 
of observations, so similar clusters can be merged together. 
Ward’s linkage—using analysis of variance as the distance 
measure between clusters—was applied. A graphical illustra-
tion of the clustering algorithm results in a tree hierarchical 
diagram or a “dendrogram,” displaying the number of likely 
clusters in a given cohort. Cutting this dendrogram at vari-
ous levels divides study subjects into a variety of partitions. 
Once the optimal number of clusters is determined, vertical 
box plots are then generated to illustrate the disposition of the 
described clusters, according to specified dimensions. Each 
dimension related to each corresponding cluster is associated 
with a particular coordinate score. The two dimensions that 
best identify each specific cluster, by optimally distinguishing 
it from other groups, are chosen. Subsequently, MCA plots—
consisting of two-dimensional scatter plots displaying each 
category of each variable as a data-point in space—are gener-
ated for each of the clusters, using the best two dimensions 
previously identified. A definition is, therefore, provided for 
each of the clusters, according to the position of each category 
for every corresponding variable on the axis of both dimen-
sions. All analyses were performed using STATA12 statistical 
software package.
MCA was implemented by choosing 10 variables, con-
sisting of demographic, clinical, pathologic, and metabolic 
parameters, found—after our review of the literature—to be 
potentially prognostic in patients with NSCLC. All variables 
were categorical, either ordinal or nominal, except for age 
and standardized uptake value (SUV) on positron emission 
tomography–computed tomography (PET–CT). Such vari-
ables were converted to categorical parameters for the purpose 
of MCA. The variable “age” was subdivided into six catego-
ries. As for the SUV, we set the threshold at the median value 
as previously described.9 Such threshold divides patients into 
subjects having a tumor with “high” metabolism or SUV and 
those with a tumor of “low” SUV. The variable representing 
“Eastern Cooperative Oncology Group Performance Status” 
(ECOG PS)—a five-point scale measuring an individual’s 
level of functioning and capability of self-care—was con-
verted to a three-level parameter, with the following catego-
ries: PS of “0,” PS of “1”—including those whose PS was 
entered in the database as “0–1” or “1” or “missing”—and 
a PS of “2 or more,” which comprised subjects with a PS of 
“1–2” or “2 or more.” A “missing” category was generated for 
each variable with missing data. When a given variable con-
tained only few missing observations, such missing data were 
included in the category with the largest number of observa-
tions. Missing categories and observations were taken into 
account and included in the analysis.
OS and DFS time for each of the identified clusters was 
estimated from the date of diagnosis to the date of death or 
disease recurrence, using the Kaplan–Meier method. When 
neither death nor disease recurrence occurred, data were cen-
sored at the date of last follow-up appointment. Cox’s propor-
tional hazard modeling was carried out to compare OS and 
DFS estimates between clusters, before and after adjusting 
for the variable age. Hazard ratios (HR) for survival estimates 
were deemed statistically significant when the 95% confi-
dence interval (CI) did not include one, and when p-value was 
less than 0.05.
We also performed multivariable Cox regression model 
analyses, separately for OS and DFS with “stage,” categorized 
to three levels (I, II, and III) as the main factor, adjusting for 
gender, weight loss, PS, differentiation, histology, thyroid 
transcription factor 1 (TTF-1) staining, SUV, and smoking sta-
tus. Cross-validation of the Cox regression models was done 
to assess validation and calibration, by computing Somer’s 
Dxy correlation coefficient and the slope shrinkage, with the 
bootstrap method.10 To perform such analysis, we used the R 
software.11,12
RESULTS
Subject Demographics
The initial data set included a cohort of 382 subjects con-
sisting of all consecutive patients diagnosed between January 
2004 and December 2010. Fifteen patients were subsequently 
excluded for the following reasons: recurrent disease at initial 
entry in the cohort (10 patients), final surgical tissue histology 
only revealing squamous dysplasia (one patient) or squamous 
cell carcinoma in situ (one patient), mixed histological entity 
of sarcomatoid carcinoma and poorly differentiated adenocar-
cinoma (ADK) (one patient), a second metachronous primary 
tumor (one patient), and missing and irretrievable important data 
(one patient). The final study population thus consisted of 367 
subjects. Subjects’ baseline characteristics are shown in Table 1.
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Cluster Analysis
The MCA output showed that a one-dimensional solu-
tion accounts for 46.7% of the total explained variance, with 
an eigenvalue of 0.032. A second dimension would contribute 
an additional 9.5% of the variance; a third dimension would 
further add 6.5% of the variance; and a fourth one would only 
explain 3.7% of the latter. A three-dimensional solution was 
adopted, producing an equivalent number of coordinates.
Using hierarchical cluster analysis, cluster trees or “den-
drograms” were generated, as described previously. Using a 
three-dimensional solution, a four-cluster model seemed to 
best illustrate our patient cohort.
Four-Cluster Model
A dendrogram illustrating the four-cluster model, which 
corresponds to the three-dimensional MCA solution, is shown 
in Figure 1. A vertical box plot was subsequently drawn, 
showing the disposition of identified clusters, according to 
each of the three dimensions (Figure 2). An MCA plot was 
then generated for every cluster, indicating the distribution of 
categorical variables in accordance with the best two dimen-
sions previously selected (Figure 3).
Demographic and baseline clinical and pathologic 
characteristics of the identified clusters are depicted in 
Table 1. In this four-cluster model, phenotypic groups were 
identified as follows: cluster 1 (n = 170) consisted mainly of 
current or former smokers, presenting with weight loss, and 
poorly or moderately differentiated ADK and squamous cell 
carcinoma. Patients in cluster 2 (n = 48) were also current 
or former smokers, presenting with more advanced disease 
stages (mainly IIIA and IIIB), undifferentiated or poorly dif-
ferentiated histology, mostly positive TTF-1 staining, and 
high SUV. Cluster 3 (n = 108) included more male subjects, 
current/former smokers, with a good or moderate PS, poorly 
TABLE 1.  Baseline Characteristics of Clusters in the Four-
Cluster Model
Total 
Cohort Cluster 1 Cluster 2 Cluster 3 Cluster 4
Number of 
subjects
367 170 48 108 41
Age
  0–39 4 (1.1) 1 (0.6) 0 0 3 (7.3)
  40–49 16 (4.4) 6 (3.5) 6 (12.5) 3 (2.8) 1 (2.4)
  50–59 76 (20.7) 17 (0.1) 11 (22.9) 31 (28.7) 17 (41.5)
  60–69 101 (27.5) 38 (22.4) 11 (22.9) 45 (41.7) 7 (17.1)
  70–79 123 (33.5) 64 (37.6) 17 (35.4) 29 (26.9) 13 (31.7)
  80–89 47 (12.8) 44 (25.9) 3 (6.3) 0 0
Gender
  Male 191 (52) 90 (52.9) 27 (56.3) 65 (60.2) 9 (22)
  Female 176 (48) 80 (47.1) 21 (43.8) 43 (39.8) 32 (78)
Smoking status
  Current 137 (37.3) 63 (37.0) 21 (43.8) 45 (41.7) 8 (19.5)
  Former/ 
missing
187a (51) 89 (52.4) 25 (52.1) 52 (48.1) 21 (51.2)
  Never 43 (11.7) 18 (10.6) 2 (4.1) 11 (10.2) 12 (29.3)
Weight loss
  Yes 171 (46.6) 73 (42.9) 28 (58.3) 58 (53.7) 12 (29.3)
  No 132 (36) 50 (29.4) 19 (39.6) 40 (37.0) 23 (56.1)
  Missing 64 (17.4) 47 (27.6) 1 (2.08) 10 (9.3) 6 (14.6)
ECOG PS
  0 134 (36.5) 48 (28.2) 16 (33.3) 36 (33.3) 34 (82.9)
  1 or missing 188a (51.2) 87 (51.2) 24 (50) 71 (65.7) 6 (14.6)
  2 45 (12.3) 35 (20.6) 8 (16.7) 1 (0.9) 1 (2.4)
Disease stage
  IA 55 (15.0) 19 (11.2) 0 14 (13) 22 (53.7)
  IB 58 (15.8) 45 (26.5) 0 8 (7.4) 5 (12.2)
  IIA 36 (9.8) 9 (5.3) 0 26 (24.1) 1 (2.4)
  IIB 41 (11.2) 16 (9.4) 9 (18.8) 14 (13) 2 (4.9)
  IIIA 95 (25.9) 37 (21.8) 21 (43.8) 29 (26.9) 8 (19.5)
  IIIB 82 (22.3) 44 (25.9) 18 (37.5) 17 (15.7) 3 (7.3)
Histology
  ADK/missing 220a (60) 87 (51.2) 18 (37.5) 89 (82.4) 26 (63.4)
  ADK in situ 17 (4.6) 3 (1.8) 0 0 14 (34.1)
  ADK squamous 6 (1.6) 5 (2.9) 0 1 (0.9) 0
  Squamous 71 (19.4) 63 (37.1) 0 7 (6.5) 1 (2.4)
  Undiff./large 35 (9.5) 4 (2.4) 29 (60.4) 2 (1.9) 0
  Others 18 (4.9) 8 (4.7) 1 (2.1) 9 (8.3) 0
Differentiation
  No or poor 145 (39.5) 36 (21.2) 47 (97.9) 53 (49.1) 9 (22)
  Moderate 93 (25.3) 47 (27.6) 0 44 (40.7) 2 (4.9)
  Well 34 (9.3) 5 (2.9) 0 3 (2.8) 26 (63.4)
  Missing 95 (25.9) 82 (48.2) 1 (2.1) 8 (7.4) 4 (9.8)
TTF-1 staining
  Positive 173 (47.1) 37 (21.8) 24 (0.5) 81 (75) 31 (75.6)
  Negative 66 (18) 39 (22.9) 7 (14.6) 14 (13) 6 (14.6)
  Missing 128 (34.9) 94 (55.3) 17 (35.4) 13 (12) 4 (9.8)
SUV
  Low 123 (33.5) 57 (33.5) 5 (10.4) 40 (37) 21 (51.2)
  High 122 (33.2) 50 (29.4) 14 (29.2) 56 (51.9) 2 (4.9)
  Missing 122 (33.2) 63 (37.1) 29 (60.4) 12 (11.1) 18 (43.9)
A “missing” category was created for all variables, when missing data were observed. 
If few missing data were observed for a given variable, such missing observations 
were added to the category containing the most subjects.
ECOG PS: category 1 included database entries recorded as “0–1” and “1,” and 
missing data; category 2 included the following entries: “1–2,” “2,” “2–3,” “3,” “3–4,” 
and “4.”
SUV uptake: Converted to a categorical variable, by computing the median SUV 
uptake. The median SUV uptake was found to be 8.65; low SUV uptake was therefore 
defined as below 8.65, and high SUV uptake was defined as ≥ 8.65.
TTF-1 staining: the category “positive” included also specimens reported as weakly 
positive. 
ADK: category “Others” included the following: large cell with neuroendocrine 
tumor and pleomorphic/sarcomatoid carcinoma.
aNumber of subjects in the total cohort for whom the following data were missing: 
smoking status (n = 7), ECOG PS (n = 15), and histology (n = 12); number of subjects 
in the surgical subcohort for whom data were missing: smoking status (n = 0), PS (n = 6), 
and histology (n = 0).
ECOG PS, Eastern Cooperative Oncology Group Performance status; ADK, 
adenocarcinoma; TTF-1, thyroid transcription factor; SUV, standardized uptake value.
(Continued )
Total 
Cohort Cluster 1 Cluster 2 Cluster 3 Cluster 4
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or moderately differentiated histology, and mainly ADK 
exhibiting positive TTF-1 protein expression. Cluster 4 (n = 41) 
was a unique group consisting of females, with a significant 
proportion of never-smokers, presenting with a good PS and 
no weight loss, early stage (1A) well-differentiated ADK and 
ADK in situ (formerly known as bronchioloalveolar), posi-
tive TTF-1 staining, and low metabolic activity on PET.
Outcome Assessment
As previously outlined, Kaplan–Meier survival curves 
were generated for OS and DFS for each of the identified 
clusters.
Overall and Disease-Free Survival 
in the Total Cohort
Follow-up data were missing for 11 individuals; sur-
vival analysis was, therefore, undertaken on a cohort of 356 
subjects. Patients were followed for a mean of 2.5 years, and 
173 subjects died during that period (191 deaths per 1000 per-
son-years). Five-year cumulative OS and DFS were 43% and 
30%, respectively. Kaplan–Meier OS curves are depicted by 
disease stage in Figure 4.
Overall and Disease-Free Survival 
in the Four-Cluster Model
Kaplan–Meier 3-year and 5-year OS and 5-year DFS 
curves for this four-cluster model are illustrated in Figures 5, 6 
and 7, respectively. Cox-proportional hazards modeling shows 
a significantly worse OS in clusters 1, 2, and 3 with HR of 
mortality of 4.98 (95% CI: 2.30–10.77), 8.09 (95% CI: 3.54–
18.49), and 3.68 (95% CI: 1.66–8.15), respectively, when 
compared with cluster 4 as the reference (Table 2). It is worth 
noting that cluster 4 was chosen as the reference category, 
given that it carries the best prognosis. Similar findings were 
observed for DFS estimates, as clusters 1, 2, and 3 showed 
HR of recurrence of 2.24 (95% CI: 1.34–3.75), 4.50 (95% CI: 
2.50–8.10), and 2.24 (95% CI: 1.31–3.82), respectively, rela-
tive to cluster 4. Adjusting for age did not significantly alter 
OS or DFS estimates.
Four-Cluster Versus TNM Staging System Model
Multivariable Cox regression model analyses were 
undertaken separately for OS and DFS with stage, catego-
rized to three levels (I, II, and III) as the main factor, adjusting 
for gender, weight loss PS, differentiation, histology, TTF-1 
staining, SUV, and smoking status. For OS, the c-index for 
the cluster model is 0.62, and the one for the multivariable 
Cox regression model is 0.78. For DFS, the c-index for the 
cluster model is 0.59 and for the multivariable model is 0.73. 
Using cross-validation, we obtain similar results. Such analy-
sis highlights the lack of additional predictive ability of the 
four-cluster model when compared with the TNM staging sys-
tem model.
DISCUSSION
Lung cancer is associated with a wide prognostic range, 
within and across disease stages. Currently, therapeutic man-
agement of patients diagnosed with NSCLC relies almost 
exclusively on the TNM staging system. The main assumption 
in this classification system is that all patients assigned to a 
particular stage have a similar clinical course and disease out-
come and should, therefore, be treated according to a similar 
FIGURE 1.  Dendrogram indicating the four-cluster model. 
The cutoff line for the cluster selection process is the red line 
shown above. Cutting the dendrogram at this level (for the 
three-dimensional solution)—thereby yielding a four-cluster 
model—was attempted. According to the selected partitions, 
cluster 1 includes the groups G1–G7 (170 subjects), cluster 2 
comprises G8 and G9 (48 subjects), cluster 3 includes G10–
G14 (108 subjects), and cluster 4 corresponds to individuals 
in the group G15 (41 subjects).
FIGURE 2.  Three-dimension, four-cluster model. This 
vertical box-plot shows the disposition of each of the four 
clusters, according to the three depicted dimensions. The 
two best dimensions that describe a particular cluster consist 
of those, which best discriminate between that cluster and 
the remaining clusters. Such dimensions should ideally have 
coordinate values far from 0, in either direction. Cluster 1 
can be differentiated from cluster 2, using dimensions 2 and 
3. Although cluster 1 has a predominantly positive axis with 
regard to dimension 2 and a negative axis with regard to 
dimension 3, cluster 2 is described by these two dimensions 
in opposite directions.
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algorithm. Such an approach overlooks distinct identifiable 
subgroups of individuals within traditional disease stages. In 
fact, despite careful assessment and staging, followed by opti-
mal surgical management, 30% of subjects with early stage I 
NSCLC, 60% of patients with stage II, and 75% of those with 
stage IIIA develop recurrent disease and die within 5 years of 
initial diagnosis.13–15 Distant metastases account for 55% to 
75% of disease recurrence rates.16 Such observations under-
score the importance of NSCLC heterogeneity. Although many 
prognostic features have been suggested in the recent literature, 
only few—TNM stage, ECOG PS—have been validated and 
are now taken into consideration in the clinical setting.
The purpose of this study was to improve our under-
standing of the phenotypic heterogeneity of NSCLC—beyond 
the TNM staging system—by attempting to identify specific 
subgroups of patients with distinct baseline characteristics, 
disease presentation, clinical course, and outcome. This 
prompted our consideration of cluster analysis techniques. To 
the best of our knowledge, this is the first study to apply prin-
ciples of cluster analysis in a cohort of lung cancer patients. 
Variables selected for the clustering algorithm were chosen on 
the basis of their potential prognostic value in NSCLC.
We performed MCA before subsequent clustering 
techniques for several reasons. MCA is a technique that only 
allows subjective judgments with regard to which param-
eters or categories on the graphical plot ought to be grouped 
together. MCA is, therefore, employed mainly as a prepro-
cessing technique, used alongside other more objective mul-
tivariate statistical methods. Cluster analysis provides a more 
solid interpretation of the graphical displays generated by 
FIGURE 3.  Multiple correspondence 
analysis plots for cluster 4, accord-
ing to dimensions 1 and 3. This plot 
depicts each variable, according to 
the coordinate values associated with 
each of its categories. Dimensions 1 
and 3 were selected to describe clus-
ter 4. Taking into account the axes of 
dimensions 1 and 3 for this cluster, 
we can provide an overall description 
of the characteristics of individuals 
that constitute each cluster. With a 
positive axis for both dimensions 1 
(vertical axis) and 3 (horizontal axis), 
cluster 4 includes individuals with 
the following characteristics: patients 
with stage 1A disease, presenting no 
weight loss, having a good perfor-
mance status (0), a well-differentiated 
ADK and ADK in situ, with positive 
TTF-1 staining, low SUV uptake, and 
who are mainly nonsmokers, young 
and of female gender.
FIGURE 4.  Five-year overall survival by disease stage.
FIGURE 5.  Three-year overall survival rates in the four-
cluster model.
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MCA, by allowing the identification of distinct groupings of 
subjects who share common features and disease patterns. An 
advantage of hierarchical clustering is its application without 
prior assumptions with regard to subjects’ groupings within a 
particular cohort.
We identified a four-cluster model in our cohort. The 
identified clusters support the significant heterogeneity in 
NSCLC and suggest relevant differences in baseline demo-
graphic, clinical, pathologic, and molecular mechanisms. 
Specific disease patterns are shown, allowing the detection of 
interrelationships among the various disease features. Clusters 
were mainly distinguished from each other, on the basis of 
gender, smoking status, TNM stage, level of histologic tissue 
differentiation, metabolic activity on PET, and TTF-1 reactiv-
ity on immunohistochemistry.
A unique phenotype consisted of younger females, 
never-smokers, with early stage well-differentiated histol-
ogy—more commonly ADK—positive TTF-1 reactivity, and 
low metabolic activity on F-18 fluorodeoxyglucose (FDG)-
PET. The characteristics of such a phenotype are consistent 
with previous findings, as women with lung cancer have been 
shown to be more often never-smokers, younger at initial pre-
sentation, and to have proportionally more ADK than men.17–19 
Therefore, the identification of such a phenotype goes clearly 
beyond TNM classification system. Our analysis provided a 
classification algorithm that is based on a larger set of char-
acteristics, therefore, allowing a broader definition for each 
of the identified subgroups. A more precise determination of 
long-term outcome and disease prognosis was expected, when 
using a classification scheme that encompasses a wider range 
of important baseline features.
Although differences in baseline characteristics were 
more subtle among the other clusters, specific disease pat-
terns were described. Both clusters 1 and 3 included predom-
inantly former or current smokers with poorly differentiated 
histology. In comparison to cluster 1, subjects assigned to 
cluster 3 were more likely to be of male gender and to have 
ADK with positive TTF-1 staining. Cluster 2 consisted of 
subjects with more advanced disease stages (IIA/IIIB), 
with higher metabolic activity on PET. Again, these find-
ings are consistent with previously published results, which 
have shown that active or former smokers with lung can-
cer are predominantly male subjects with more advanced 
disease stages.20 To our knowledge, no previous studies 
have explored the correlation between smoking status and 
tumor grade or level of differentiation among subjects with 
NSCLC. The clustering algorithm clearly shows such an 
association. This is particularly interesting, as this approach 
might allow the identification of other previously unknown 
associations, thereby generating hypotheses that could be 
validated through further research.
Survival analysis shows that cluster 4 (young, female, 
never smokers with IA disease stage, well-differentiated 
tumor, positive TTF-1, and low metabolic activity) is associ-
ated with a favorable prognosis, with longer 5-year OS and 
DFS, when compared with the other three clusters. Again, 
these data support previous findings, which suggest that 
younger age,19,21–23 female gender,17,24–26 never-smoking sta-
tus,27,28 early stage ADK,29,30 well-differentiated tumor,31 and 
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FIGURE 6.  Five-year overall survival rates in the four-cluster 
model.
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FIGURE 7.  Five-year disease-free survival rates in the four-
cluster model.
TABLE 2.  Cox-Proportional Hazards Ratios for Mortality and Recurrence in the Four-Cluster Model
Hazard Ratio Mortality
95% Confidence 
Interval
Hazard Ratio 
Recurrence
95% Confidence 
Interval P Values
Four-cluster model
  Cluster 1 4.98 2.30–10.77 2.24 1.34–3.75 <0.0001
  Cluster 2 8.09 3.54–18.49 4.50 2.50–8.10 <0.0001
  Cluster 3 3.68 1.66–8.15 2.24 1.31–3.82 0.0013
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positive TTF-1 staining32,33 are favorable prognostic features 
in NSCLC.
This is the first study to explore the application of clus-
tering algorithms for the identification of lung cancer pheno-
types. A major strength in our study is the unsupervised nature 
of the analysis, allowing cluster identification without any a 
priori assumption. A uniquely favorable disease pattern was 
clearly identified and distinguished from all the other groups, 
in accordance with previous findings. Association between 
specific characteristics—namely female gender, ADK, and 
never-smoking status—which has only been highlighted 
recently in the medical literature—was clearly shown here, 
as such features were part of a specific cluster. In addition to 
defining distinct phenotypic groups derived from baseline fea-
tures, we further sought to investigate these groups by assess-
ing outcome. Interestingly, our analysis has shown that cluster 
assignment at baseline was predictive of long-term outcome, 
specifically OS and DFS. However, when comparing our four-
cluster model to a multivariate regression model stratifying 
by stage, there was no evidence that the clustering algorithm 
provides any additional predictive value to the TNM staging 
system. A major limitation of the current study, however, is 
the sample size. A larger study population could have allowed 
us to identify specific and more distinct clusters within each of 
the TNM stages, therefore, providing an additional predictive 
potential to the TNM classification system.
We acknowledge that this study has some weaknesses. 
Our cohort consisted of a relatively small number of subjects 
as mentioned above, therefore, lacking the power to detect 
distinct clusters. Larger studies might allow the identification 
of a greater number of subgroups, within each disease stage. 
Another potential limitation is the subjective nature of assess-
ments at various steps in the analysis—namely selection of 
variables to include in the cluster analysis, choice of the opti-
mal number of dimensions after MCA, and the best number 
of clusters in a given dendrogram. There is no formal method 
to assess the optimal number of clusters that best describe a 
data set. Some clusters included subjects with a variety of 
disease stages; this is particularly concerning, given that dis-
ease stage—according to the TNM classification system—is 
the most important prognostic factor to date, allowing clini-
cal decision-making with regard to management algorithms. 
Again, a larger sample might have allowed more optimal dis-
tinction among clusters, by identifying subgroups of patients 
within each particular disease stage. Further investigation of 
our clustering algorithm—and in particular, relation to out-
come—is, therefore, required in larger cohorts.
Using hierarchical clustering techniques, we were able 
to identify specific clusters with distinct clinical phenotypes, 
in a cohort of patients with stages I to III NSCLC. Clusters 
consisted of specific disease patterns, with respect to baseline 
demographic, clinical, pathologic, and molecular features. 
Further assessment of the identified clusters was feasible, by 
analyzing and comparing outcome data between such group-
ings. In many instances, statistically significant differences 
in OS and DFS were observed between clusters. This indi-
cates that baseline cluster assignment was indeed predictive 
of long-term outcome in this cohort.
These findings highlight the complexity and heteroge-
neous aspect of NSCLC and emphasize the need of better 
approaches to conceive a more elaborate and comprehensive 
classification algorithm, which takes into account the various 
aspects of this disease entity. Future efforts should focus on 
designing larger studies that further assess the application of 
clustering algorithms in cohorts of NSCLC patients.
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